Scientist – Molecular Pharmacology, Drug Discovery & Development with 6+ years of experience integrating proteogenomic profiling, CRISPR screening, and preclinical modeling. Proven success in drug screening, target identification, resistance mechanism characterization, supporting preclinical drug discovery, and optimizing combination therapies to enhance translational outcomes. I bring strong expertise in mechanistic biology and translational research to guide data-driven pipeline decisions and improve clinical outcomes. Selected for the National Institutes of Health (NIH) Visiting Fellow Award at the Center for Cancer Research (CCR), National Cancer Institute (NCI), based on a strong record of scientific productivity. Currently leading translational research to support preclinical drug development in hematologic malignancies. My research employs proteogenomic technologies and biochemical approaches to uncover molecular mechanisms of pathogenic signaling in multiple myeloma. I aim to identify therapeutic targets, elucidate resistance mechanisms, and explore treatable pathways for improved targeted treatment. I also perform pharmacodynamic assessments to study dose-response relationships and evaluate the efficacy, potency, and toxicity of various agents and combination therapies.